PINK
CLPBY

Coloplast A

Medical Instruments & Supplies
Healthcare

Prices are adjusted according to historical splits.

Coloplast A Stock Price

Vitals

Today's Low:
$11
Today's High:
$11.08
Open Price:
$11.045
52W Low:
$9.5575
52W High:
$14.5699
Prev. Close:
$11.19
Volume:
91107

Company Statistics

Market Cap.:
$26.57 billion
Book Value:
3.3115
Revenue TTM:
$24.07 billion
Operating Margin TTM:
29.2%
Gross Profit TTM:
$15.53 billion
Profit Margin:
19.94%
Return on Assets TTM:
12.47%
Return on Equity TTM:
67.11%

Company Profile

Coloplast A had its IPO on under the ticker symbol CLPBY.

The company operates in the Healthcare sector and Medical Instruments & Supplies industry. Coloplast A has a staff strength of 14,973 employees.

Stock update

Shares of Coloplast A opened at $11.05 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $11 - $11.08, and closed at $11.03.

This is a -1.43% slip from the previous day's closing price.

A total volume of 91,107 shares were traded at the close of the day’s session.

In the last one week, shares of Coloplast A have slipped by -3.42%.

Coloplast A's Key Ratios

Coloplast A has a market cap of $26.57 billion, indicating a price to book ratio of 22.4646 and a price to sales ratio of 1.1347.

In the last 12-months Coloplast A’s revenue was $24.07 billion with a gross profit of $15.53 billion and an EBITDA of $7.77 billion. The EBITDA ratio measures Coloplast A's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Coloplast A’s operating margin was 29.2% while its return on assets stood at 12.47% with a return of equity of 67.11%.

In Q1, Coloplast A’s quarterly earnings growth was a positive 18.2% while revenue growth was a positive 10.2%.

Coloplast A’s PE and PEG Ratio

Forward PE
33.3333
Trailing PE
37.8485
PEG
3.3942

Its diluted EPS in the last 12-months stands at $0.33 per share while it has a forward price to earnings multiple of 33.3333 and a PEG multiple of 3.3942. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Coloplast A’s profitability.

Coloplast A stock is trading at a EV to sales ratio of 1.2771 and a EV to EBITDA ratio of 3.9889. Its price to sales ratio in the trailing 12-months stood at 1.1347.

Coloplast A stock pays annual dividends of $20 per share, indicating a yield of 2.26% and a payout ratio of 88.18%.

Balance sheet and cash flow metrics

Total Assets
$35.30 billion
Total Liabilities
$9.43 billion
Operating Cash Flow
$0
Capital Expenditure
$291 million
Dividend Payout Ratio
88.18%

Coloplast A ended 2024 with $35.30 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $35.30 billion while shareholder equity stood at $7.03 billion.

Coloplast A ended 2024 with $0 in deferred long-term liabilities, $9.43 billion in other current liabilities, 216000000.00 in common stock, $6.57 billion in retained earnings and $0 in goodwill. Its cash balance stood at $628.00 million and cash and short-term investments were $644.00 million. The company’s total short-term debt was $4,606,000,000 while long-term debt stood at $16.39 billion.

Coloplast A’s total current assets stands at $9.32 billion while long-term investments were $0 and short-term investments were $16.00 million. Its net receivables were $3.99 billion compared to accounts payable of $1.14 billion and inventory worth $3.51 billion.

In 2024, Coloplast A's operating cash flow was $0 while its capital expenditure stood at $291 million.

Comparatively, Coloplast A paid $0.88 in dividends in 2024.

Other key metrics

Current Trading Price
$11.03
52-Week High
$14.5699
52-Week Low
$9.5575
Analyst Target Price
$

Coloplast A stock is currently trading at $11.03 per share. It touched a 52-week high of $14.5699 and a 52-week low of $14.5699. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $11.94 and 200-day moving average was $12.31 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 1.6% are held by institutions.

Frequently Asked Questions About Coloplast A

The stock symbol (also called stock or share ticker) of Coloplast A is CLPBY

The IPO of Coloplast A took place on

Similar Industry Stocks (Medical Instruments & Supplies)

Last Price
Chg
Chg%
Ecovyst Inc (ECVT)
$10.33
0.24
+2.38%
$429.6
-10.45
-2.37%
$77.47
0.32
+0.41%
$7.57
0.23
+3.13%
$23.29
0.34
+1.48%
$22.88
0.03
+0.13%
$1.33
-0.02
-1.48%
$164.5
-1.9
-1.14%
$99.74
2.94
+3.04%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Coloplast A/S develops and sells intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Interventional Urology, Voice and Respiratory Care, and Wound & Skin Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, it offers voice and respiratory products, including medical devices for neck stoma under the Provox brand; and products for tracheostoma under the TRACOE brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

Address

Holtedam 1-3, Humlebæk, Denmark, 3050